Bifidobacterium animalis subsp. lactis BB-12 and Improved Immune Response to Influenza Vaccination

Doses used in studies

CFU/day: 1.3 billion–1.6 billion (median 1.4 billion, IQR 1.3 billion–1.6 billion) — 1 study

1 of 1 paper

Combination of the Probiotics Lacticaseibacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis, BB-12 Has Limited Effect on Biomarkers of Immunity and Inflammation in Older People Resident in Care Homes: Results From the Probiotics to Reduce Infections iN CarE home reSidentS Randomized, Controlled Trial.

2021-03-04
RCT · n = 30
Frontiers in immunology 12
- Vivian M Castro-Herrera
- Helena L Fisk
- Mandy Wootton
- Mark Lown
- Eleri Owen-Jones
- Mandy Lau
- Rachel Lowe
- Kerenza Hood
- David Gillespie
- F D Richard Hobbs
- Paul Little
- Christopher C Butler
- Elizabeth A Miles
- Philip C Calder

PubMed: 33746986
DOI: 10.3389/fimmu.2021.643321

3 Insights on

Improved Immune Response to Influenza Vaccination

High evidence

There was an indication that the probiotics improved the response to seasonal influenza vaccination with significantly (p = 0.04) higher seroconversion to the A/Michigan/2015 vaccine strain in the probiotic group than in the placebo group (47 vs. 15%).

Effect: Beneficial
Effect size: Small
Significant: Yes
Dose: 1.3-1.6 × 10^9 CFU per day